Company Active LTD

Company profile

Stratosvir Limited

stratosvir

Stratosvir Limited is a UK company with status active founded in 2020 based in East of England.

CRN
13099988
Founded
2020
Age
5

Overview

Legal name
STRATOSVIR LIMITED
Region
East of England
Registered address
46-54 HIGH STREET
INGATESTONE
ENGLAND
CM4 9DW
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

10 events
07 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

25 Mar
2026

Legacy

Miscellaneous

RP01SH01 | Transaction MzUwNzgzMDIwMmFkaXF6a2N4

Published 25 Mar 2026 11:35

25 Mar
2026

Legacy

Miscellaneous

RP01SH01 | Transaction MzUwNzgyODY2NWFkaXF6a2N4

Published 25 Mar 2026 11:31

12 Feb
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUwNDgwMTU1N2FkaXF6a2N4 | Paper/PDF filed

Published 26 Mar 2026 00:04

12 Feb
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUwNDgwMTYyOWFkaXF6a2N4 | Paper/PDF filed

Published 26 Mar 2026 00:03

24 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

25 Nov
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0NDQ5NjQ0MWFkaXF6a2N4

Published 25 Nov 2024 07:26

24 Dec
2020

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2023
Funded years
2023, 2024
Age at first award
2 years

Projects

2024 Collaborative R&D Lead participant

STARLITE- a novel vectorized antibody immunotherapy platform for treatment of advanced Prostate Cancer.

1 Jul 2024 to 30 Jun 2027

Awarded
£484,770
Total cost £692,529

Curing late-stage cancer though stimulation of a patient's own immune system has long been a pipedream. However, recent advances have shown that two novel classes of therapies (checkpoint inhibitor drugs; CAR-T cell therapy) can achieve exactly that, albeit in very small subsets of patients and with sometimes significant side-effects. Encouraged by these ...

2023 Grant for R&D Lead participant

CombiVir: combinatorial engineering of therapeutic viruses

1 Jul 2023 to 31 Oct 2023

Awarded
£49,935
Total cost £49,935

Curing cancer though stimulation of a patient's own immune system has long been a pipedream. However, recent advances have shown that two novel classes of therapies (checkpoint inhibitor drugs; CAR-T cell therapy) can achieve exactly that, albeit in very small subsets of patients and with sometimes significant side-effects. Encouraged by these results a h...

Product types

Collaborative R&D Grant for R&D